trending Market Intelligence /marketintelligence/en/news-insights/trending/2cAuqa--23aswbMwKGL3Ow2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Qualigen, Ritter Pharmaceuticals to merge in all-stock deal

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Qualigen, Ritter Pharmaceuticals to merge in all-stock deal

Private healthcare equipment company Qualigen Inc. agreed to merge with Ritter Pharmaceuticals Inc. in an all-stock deal.

The new company, which is expected to change its name to Qualigen Inc., will focus on developing Qualigen's nanotechnology therapies that target cancer and infectious diseases.

According to the terms of the agreement, pre-merger Ritter Pharmaceuticals' stockholders will own about 7.5% of the post-merger company while pre-merger Qualigen's stockholders will own about 92.5% of the new company.

The merger, approved by the board of both companies, is expected to be completed in the second quarter of 2020, subject to stockholder approvals.

Under a separate contingent value right agreement, the rights holder will continue to seek opportunities to monetize Ritter's experimental medication for lactose intolerance, RP-G28. Net proceeds from any potential monetization will be distributed among Ritter's pre-merger stockholders.

Los Angeles-based Ritter's stockholders of record at the time of the merger will receive nontransferable contingent value rights, giving them rights to receive proceeds from a potential sale, license, transfer, spin-off or other monetizing event of all or any part of Ritter's current business or all or any part of its intellectual property or technology entered during the period starting on the date of the deal and ending three years after closing date of the merger.

Following the merger, Qualigen's chairman, president and CEO, Michael Poirier, will be the combined company's chairman, president and CEO. The board for the combined company will have seven directors, including one member from Ritter's legacy board.

A.G.P./Alliance Global Partners is financial adviser to Ritter, while GreenBlock Capital is financial adviser to Qualigen for the transaction. Reed Smith LLP is the legal counsel to Ritter and Stradling Yocca Carlson & Rauth is legal counsel to Qualigen.